Literature DB >> 27761839

Generation and Assessment of Fusions Between HDACi and TKi.

Siavosh Mahboobi1, Bernadette Pilsl2, Andreas Sellmer2.   

Abstract

Chimeric compounds combine the structural features of inhibitors of histone deacetylases (HDACi) and tyrosine kinase inhibitors (TKi), and therefore unite the effects of a dual-targeting strategy in one compound. Here, we describe the generation of such hybrid molecules. Small molecules, known as TKi, are combined with a Zn2+ chelating motive, preferentially a hydroxamic acid, in addition. The resulting small molecules also can inhibit histone deacetylases, which are dependent on the catalytically active Zn2+. Moreover, we summarize how the growth-inhibitory effects of these combined compounds can be determined with a simple proliferation assay with a leukemic cell line.

Entities:  

Keywords:  Chimeric molecules; Dual targeting strategy; Histone deacetylase inhibitor; Hybrid structures; Proliferation assay; Tyrosine kinase inhibitor

Mesh:

Substances:

Year:  2017        PMID: 27761839     DOI: 10.1007/978-1-4939-6527-4_31

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  2 in total

Review 1.  Hybrid Drugs-A Strategy for Overcoming Anticancer Drug Resistance?

Authors:  Marta Szumilak; Anna Wiktorowska-Owczarek; Andrzej Stanczak
Journal:  Molecules       Date:  2021-04-29       Impact factor: 4.411

2.  ErbB2 Targeted Epigenetic Modulation: Anti-tumor Efficacy of the ADC Trastuzumab-HDACi ST8176AA1.

Authors:  Ferdinando Maria Milazzo; Loredana Vesci; Anna Maria Anastasi; Caterina Chiapparino; Antonio Rosi; Giuseppe Giannini; Maurizio Taddei; Elena Cini; Valentina Faltoni; Elena Petricci; Gianfranco Battistuzzi; Laura Salvini; Valeria Carollo; Rita De Santis
Journal:  Front Oncol       Date:  2020-01-23       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.